Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Molecules ; 27(20)2022 Oct 20.
Artigo em Inglês | MEDLINE | ID: mdl-36296690

RESUMO

Prostate Cancer (PCa) is the second leading cause of cancer-related deaths among men worldwide. The treatment of advanced cases is based on chemotherapy, which lacks specificity and efficacy, due to severe side effects and resistance to the traditional drugs. Copper complexes have shown antitumoral efficacy and low toxicity, being considered a promising class of metal-based drugs for the treatment of malignant neoplasms. Thus, the present study aimed to evaluate the cellular effects of a copper(II) complex with 4-fluorophenoxyacetic acid hydrazide and 1,10-phenanthroline (1) on PCa cell lines, as well as the mutagenic/recombinogenic and anticarcinogenic potential of 1 in Drosophila melanogaster. PNT-2 (non-tumorigenic), LNCaP (hormone-responsive PCa) and PC-3 (androgen-independent PCa) cells were cultured, and cytotoxicity was assessed using the MTT assay. The expression levels of the proliferation markers Ki-67 and Cyclin D1 were analyzed by flow cytometry. Furthermore, the Somatic Mutation and Recombination Test (SMART) and the Epithelial Tumor Test (ETT) were performed. Complex 1 was selective to LNCaP cells, significantly reducing Ki-67 and Cyclin D1 expression levels. Sub-toxic concentrations of complex 1 were defined by the toxicity test in D. melanogaster, and no mutagenic/recombinogenic/carcinogenic effects were observed. Anticarcinogenic potential was observed in D. melanogaster, suggesting modulating activity of the complex 1 against Doxorubicin, a drug used as control by its carcinogenic properties. Therefore, complex 1 is a possible starting point for the development of new antitumor agents for the treatment of PCa.


Assuntos
Antineoplásicos , Neoplasias da Próstata , Humanos , Masculino , Animais , Drosophila melanogaster , Cobre/farmacologia , Ciclina D1 , Hidrazinas/farmacologia , Androgênios/farmacologia , Antígeno Ki-67 , Neoplasias da Próstata/patologia , Mutagênicos/farmacologia , Carcinogênese , Antineoplásicos/farmacologia , Doxorrubicina/farmacologia , Linhagem Celular Tumoral , Proteínas de Ligação a DNA/farmacologia
2.
Int J Mol Sci ; 20(6)2019 Mar 16.
Artigo em Inglês | MEDLINE | ID: mdl-30884823

RESUMO

Triple-negative breast cancers (TNBCs) are more aggressive than other breast cancer (BC) subtypes and lack effective therapeutic options. Unraveling marker events of TNBCs may provide new directions for development of strategies for targeted TNBC therapy. Herein, we reported that Annexin A1 (AnxA1) and Cathepsin D (CatD) are highly expressed in MDA-MB-231 (TNBC lineage), compared to MCF-10A and MCF-7. Since the proposed concept was that CatD has protumorigenic activity associated with its ability to cleave AnxA1 (generating a 35.5 KDa fragment), we investigated this mechanism more deeply using the inhibitor of CatD, Pepstatin A (PepA). Fourier Transform Infrared (FTIR) spectroscopy demonstrated that PepA inhibits CatD activity by occupying its active site; the OH bond from PepA interacts with a CO bond from carboxylic acids of CatD catalytic aspartate dyad, favoring the deprotonation of Asp33 and consequently inhibiting CatD. Treatment of MDA-MB-231 cells with PepA induced apoptosis and autophagy processes while reducing the proliferation, invasion, and migration. Finally, in silico molecular docking demonstrated that the catalytic inhibition comprises Asp231 protonated and Asp33 deprotonated, proving all functional results obtained. Our findings elucidated critical CatD activity in TNBC cell trough AnxA1 cleavage, indicating the inhibition of CatD as a possible strategy for TNBC treatment.


Assuntos
Anexina A1/genética , Catepsina D/genética , Simulação de Acoplamento Molecular , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Apoptose/efeitos dos fármacos , Autofagia/efeitos dos fármacos , Domínio Catalítico/efeitos dos fármacos , Catepsina D/antagonistas & inibidores , Linhagem da Célula/efeitos dos fármacos , Linhagem da Célula/genética , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Feminino , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Células MCF-7 , Invasividade Neoplásica/genética , Invasividade Neoplásica/patologia , Pepstatinas/farmacologia , Espectroscopia de Infravermelho com Transformada de Fourier , Neoplasias de Mama Triplo Negativas/genética , Neoplasias de Mama Triplo Negativas/patologia
3.
Biosci. j. (Online) ; 26(3): 463-477, May-June 2010. ilus
Artigo em Português | LILACS | ID: lil-561959

RESUMO

As ciências ômicas tratam da análise global dos sistemas biológicos, integrando diferentes áreas do conhecimento, como a bioquímica, genética, fisiologia e computação, com o objetivo de isolar e caracterizar genes, proteínas e metabólitos, assim como estudar as interações entre eles, com base em técnicas experimentais, softwares e bancos de dados. A bioinformática por sua vez, propõe novas formas de ciência baseada na experimentação in silico, sendo muito dinâmica na sua atualização e fornecendo a base para geração de novos dados e conhecimentos que podem ser aplicados na pesquisa básica e na aplicada com o desenvolvimento de novos produtos e soluções. Este processo está intimamente relacionado à inovação tecnológica, que é conseguida unindo-se a biotecnologia e a bioinformática. Contudo, o objetivo desta revisão é apresentar uma pequena abordagem dos recursos de bioinformática aplicados às ciências ômicas, como genômica, transcriptômica, proteômica, interatômica, metabolômica, farmacogenômica, dentre outras.


The omic sciences had a wide point of view of the biological systems, integrating different knowledgement areas, as biochemistry, genetics and physiology, with the aim of isolation and characterization of genes, proteins and metabolites as well study their interactions, based on experimental techniques, softwares and data banks. Bioinformatics proposes a new science, which is based on in silico experimentation, being very dynamic in its update and also can provides the basis for generation of new data and knowledge that can be applied in basic research and applied to the development of new products and solutions. This process is closely related to technological innovation, which is achieved joining biotechnology and bioinformatics. However, the objective of this review is to present a small approach of bioinformatics resources applied to the omics science, like genomics, transcriptomics, proteomics, interatomics, metabolomics, pharmacogenomics, among others.


Assuntos
Biotecnologia , Biologia Computacional , Bases de Dados como Assunto , Genômica , Proteômica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA